Phaseline

Companies › Suzhou Zelgen Biopharmaceuticals

Suzhou Zelgen Biopharmaceuticals: clinical trials, targets and expected readouts

6 active drug programs in 24 registered trials: 20 Phase 1, 2 Phase 3, 2 Phase 2; Oncology, Immunology, Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ZG006–Phase 3Small-cell Lung Cancer; Neuroendocrine Carcinoma; Small Cell Lung CancerDec 2026
Jaktinib Hydrochloride Tablet
JAK inhibitor
JAK1, JAK2, JAK3Phase 3Atopic Dermatitis–
ZG005
Unclear - biological investigational drug for solid tumors
–Phase 2Advanced Solid Tumor; Biliary Tract Carcinoma; Lymphoma; Non-small Cell Lung Cancer …Apr 2027
ZGGS18–Phase 1Advanced Solid TumorNov 2026
Gecacitinib
Tyrosine kinase inhibitor targeting EGFR
EGFRPhase 1Healthy; Lymphoma; Non-small Cell Lung Cancer; Cervical Cancer …Feb 2027
ZGGS34
anti-MUC17 monoclonal antibody
MUC17Phase 1Solid TumorDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05526222Jaktinib Hydrochloride TabletPhase 3Atopic DermatitisImmunologyAug 2025
NCT06440057ZG006Phase 1Neuroendocrine CarcinomaOncologyMay 2026
NCT05978284ZG006Phase 1Small Cell Lung CancerOncologySep 2026
NCT05584800ZGGS18Phase 1Advanced Solid TumorOncologyNov 2026
NCT06592638ZG006Phase 1Small Cell Lung CancerOncologyDec 2026
NCT07565597GecacitinibPhase 1HealthyOtherFeb 2027
NCT07012304GecacitinibPhase 1Chronic Graft Versus Host DiseaseImmunologyFeb 2027
NCT06283719ZG006Phase 1Small Cell Lung CancerOncologyApr 2027
NCT06883526ZG005Phase 1LymphomaOncologyApr 2027
NCT06903377ZG005Phase 1Non-small Cell Lung CancerOncologyApr 2027
NCT06883526GecacitinibPhase 1LymphomaOncologyApr 2027
NCT06903377GecacitinibPhase 1Non-small Cell Lung CancerOncologyApr 2027
NCT06938880ZGGS18Phase 1Advanced Solid TumorOncologyMay 2027
NCT06927687ZG005Phase 2Advanced Solid TumorOncologyMay 2027
NCT06938880ZG005Phase 1Advanced Solid TumorOncologyMay 2027
NCT07080216ZG005Phase 1Cervical CancerOncologyAug 2027
NCT07080216GecacitinibPhase 1Cervical CancerOncologyAug 2027
NCT07038096ZG006Phase 1Small Cell Lung CancerOncologySep 2027
NCT07038096ZG005Phase 1Small Cell Lung CancerOncologySep 2027
NCT07099547ZG005Phase 2Biliary Tract CarcinomaOncologyDec 2027
NCT07189455ZG006Phase 3Small-cell Lung CancerOncologyOct 2028
NCT07883382GecacitinibPhase 1Myeloid Neoplasms With MyelofibrosisOncologyOct 2028
NCT07231445ZG006Phase 1Small Cell Lung CancerOncologyDec 2028
NCT07258121ZGGS34Phase 1Solid TumorOncologyDec 2028

Targets

MUC17 (1) EGFR (1) JAK1 (1) JAK2 (1) JAK3 (1)

Companies with the same targets

Pfizer AbbVie AstraZeneca Incyte Dizal Pharmaceuticals Shanghai Henlius Biotech Chia Tai Tianqing Pharmaceutical Group Takeda Allist Pharmaceuticals Betta Pharmaceuticals

Companies built like this

Dizal Pharmaceuticals Hansoh BioMedical R&D Company Shanghai JMT-Bio Jiangsu Alphamab Biopharmaceuticals Jiangsu Aosaikang Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.